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A number of 2-(9-acridinylamino)pyridines 1 and
2-( 9-acridinylaminolimino )thiazolines 2 and 3 have
been synthesized by the condensation of 9-chloro-
acridines with 2-aminopyridine, 2-amino-2-thiazoline
and 3, 4-diaryl-2-imino-4-thiazoline, respectively. The
resulting products have been evaluated for their anti-
inflammatory and analgesic activities. Compound 3j
shows good analgesic activity.
Acridine based antimalarial and antibacterial
compounds (mepacrine, azacrine, proflavine and
aminacrine) are known'. 9-[(Dimethylaminopro-
pyl )amino ]-l-nitroacridine has been quite extens-
ively used as an antitumor drug in Poland. Am-
sacrine has a wide-spread clinical use as an anti-
tumor agent ':". Denny and co-workers have been
deeply involved in the synthesis and antitumor
evaluation of acridine derivatives-:". Acridine der-
ivatives exhibiting fungicidal?'!', antimicrobial'F:"
antiparasitic I,) and anti-inflammatory IS activities
are reported in literature. In continuation of our
efforts in the search of potential anti-inflammato-
ry compounds Ifi-21, we wish to report here the
synthesis and anti-inflammatory and analgesic ac-
tivity screening of a number of acridine deriva-
tives (1-3).
The required 9-chloroacridines were synthes-
ized by the condensation of N-arylanthranilic ac-
ids21 with phosphorus oxychloride+'. Condensa-
tion of t/-chloroacridine and 9-chloro- 2-methylac-
ridine with 2-aminopyridine in methanol under
reflux for 8 hr followed by purification by crystal-
lization and chromatography over silica gel gave
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the corresponding acridinylaminopyridines 1a and
Ib (Scheme I).
Condensation of 9-chloroacridine and 9-chloro-
2-methylacridine with 2-amino-2-thiazoline in
methanol under reflux for 16 hr followed by puri-
fication by column chromatography over silica gel
gave the corresponding acridinylamino-2-thiazo-
lines 2a and 2b (Scheme I). For structures 2a and
2b, the molecular ion peaks were obtained at m/z
219.08292 and 293.09880 (calculated values for
CI6H13N3S and C17H1SN3S are m/z 279.08301
and 293.09866, respectively).
3, 4-Diaryl-2-imino-4-thiazolines, prepared by
the condensation of phenacyl thiocyanate and amine
hydrochlorides as reported in literature.", on con-
densation with 9-chloroacridines in methanol un-
der reflux for 10 hr followed by purification by
chromatography over silica gel gave the acridinyli-
mino-4-thiazolines 3a-3m (Scheme I). The struc-
tures of all the synthesized compounds 1-3 were
supported by their IH NMR, HRMS and IR
spectra (cf. Table I).
All the compounds synthesized were evaluated
for their anti-inflammatory and analgesic activit-
ies. Compounds 3c, 3d, 3e and 3f showed weak
analgesic activity and compounds I b, 2b and 3e
showed weak anti-inflammatory activity. However,
compound 3j showed a good analgesic activity.
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Experimental Section
Melting points were determined on a JSGW ap-
paratus and are uncorrected. Only principal
sharply defined IR peaks are reported. IH NMR
spectra were recorded in DMSO-d6 solutions (5-
15%, w/v) with TMS as internal standard. MS
peaks were measured by comparison with that of
perfluorotributylamine at a resolving power of
15,000. lLC was performed over silica gel G
(Merck) coated plates and spots were visualized
by iodine vapours or by irradiation with UV light
of 254 nm wavelength. Silica gel ,(60-120 mesh)
was used for column chromatography. Elemental
analyses (C, H, N) were within ± 0.4% of theoret-
ical values.
Condensation of 2-aminopyridine with
9-chloroacridine:Formation of la. 9-Chloroacri-
dine (426 mg, 2mmoles) was dissolved in metha-
nol (30 mL) and to it was added 2-aminopyridine
(190 mg, 2mmoles). The reaction mixture was
heated under reflux for 8 hr, and then solvent re-
moved under reduced pressure. The solid residue
Table I-Physical and spectral data of acridine derivatives 1-3
Compd m.p. °C (solvent of Yield
crystallization/elution). (%)t
la 180 30
(w)
Ib 220 36
(w-x; 8:2)
2a 19~95 30
(y-w; 2:8)
2b 225 52
(z-w; 5:5)
Spectral data
'H NMR: ()7.0 «. 2H, Ar), 7.3 (m, 2H, Ar), 8.0(m, 7H,Ar), 8.2(m, IH, Ar),
13.2(s, IH, - NH -, exch.).
HRMS (m/z; reI. int.):271. 10915 (M+; 100.00) (CaJcd for C,sH13N3:271.11096),
270.10216 (M· - H, 98.83),178.06433 (M· - C5H5Nz; 3.51),78.03472 (C5H4N;
3.99).
IH NMR:() 2.40 (s, 3H, - CH3), 7.2 (t, 2H, Ar). 7.5(m, 5H, Ar), 7.7(t, 2H, Ar),
8.0(s, IH, Ar), 8.2(d, l H, Ar), 11.6(s, IH, - NH -, exch).
HRMS (m/z; reI. int.): 285.12545 (M+; 100.00) (CaJcd. for CI9HI5N3:285.12659),
284.11827(M+ - H; 73.99), 270.10375 (M+ - CH3; 21.51),
207.09119(M+ - C5H4N; 8.95), 78.03418 (C5H4N; 9.60).
'H NMR: ()3.3(t, 2H, - CH2 - ), 3.65(t, 2H, - CH2 -). 7.5(m:2H, Ar),
7.75(m, 2H, Ar), 8.0(d, 4H, Ar), 8.2(s, IH, - NH -, exch).
HRMS(m/z; reI. int.): 279.08292 (M+:100.00XCaIcd for CI6H13N3S: 279.08301),
278.07528(M+ -H; -'.
NA-CN 1+
34.74), 251.05145.(M+ -CHz=CH2; 4.15), 219.07983( 00g ;34.98).
IHNMR: () 3.30(t, 2H, -CHz-), 3.65 (t, 2H, -CH2-), 7.45 (rn, IH,Ar),
7.60(dd, IH, Ar), 7.7 (rn, tH, Ar), 7.80(s, tH, Ar) 8.00(m, 3H, Ar), 8.15(bs, tH,
- NH -exch.) signal due to methyl group is merged with DMSO signal at 2.50.
HRMS (m/z; reI. int.): 293.09880 (M+; 100.00) (Calcd. for
C17HI5N]S:293.09866, 292.09135 (M+ - H; 31.4~, 265.06678
N~CN'+
(M+ -CH2=CH2;~.98),233.09578( ~Mc ;30.51),
192.08009 ~M. ; 11.36).
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Table I-Physical and spectral data of acridine derivatives 1-3
Compd m.p. ·C (solvent of Yield Spectral data
crysta1lization/elution)* (%)t
27.25),77.03854 (C6H;; 29.22)
25 'HNMR: b 2.30 (s, 3H, CH3), 6.5(s, lH, >C-CH), 7.2(d, 7H,Ar),
7.5(m, 5H, Ar), 7.75(m, 2H, Ar), 8.10(m, 3H, Ar).
HRMS (m/z.rel. int.): 443.14563(M+; l00.00XCalcd. for
CzJiz,N3S:443.14563), 442.13783 (M+ - H; 15.21), 91.05477(C7H7; 32.52),
77.03843(C6H;; 3.76).
60 IHNMR: b2.55 (5, 3H, -CH]),6.50(s, IH, >C-CH -), 7.2(m, 5H,Ar),
7.30{m, lH, Ar), 7.45(m, 3H, Ar), 7.60{m, 3H, Ar), 7.70(m, 2H, Ar), 8.O{m, 3H,
Ar)
HRMS (m/z: reI. int.) :443.14485(M+; 100.00XCaled for CzJizIN]S:443.14563),
251.06239(ClsHIINzS; 4.02).
11 IHNMR: b3.80(s, 3H, -OCH])6.9-7.7(m,17H,Ar+1H, >C=CH-).
HRMS (rn/z; reI. int.): 459.14076(M+; 46.38XCalcd. for
CzJizIN]SO:459.14053), 444.11733 (M+ -CH); 11.34),
~OM'251.06468(M' - ~~ ; 100.00),77.03921 (C6H;;44.20)
16 'H NMR: b 3.69(s, 3H, - OCH]), 6.40(5, IH, > C = CH -), 6.83(d, 2H, Ar),
7.16(d, 2H, Ar), 7.48(m, 5H, Ar), 7.61(d, 2H, Ar), 7.79(m, 2H, Ar), 8.05(d, 3H,
Ar), 8.20(d, IH, Ar).
IR(KBr)cm-': 1606( > C -N -),1551 and 1506 (Ar),
16 IHNMR: 6 3.73 (s,3H, -OCH]),6.47(s, IH, >C-CH-), 7.02(d, 2H,Ar),
7.29\m, 4H, Ar), 7.54(m, 4H, Ar), 7.79\m, 3H, Ar), 8.05(d, 3H, Ar),
8.21(d, 1H, Ar).
IR(KBr) em-I; 1599 (>C -N -),1551 and 1508 (Ar).
24 'H NMR: M.5 (5, IH, > C - CH - ), 7.30 (m, 8H, Ar), 7.52(m, 4H, Ar),
7.70(m, 3H, Ar), 8.05(d, 2H, Ar).
IR(KBr) em-I: 1615 (> C-N -),1586 and 1551 (Ar).
16 'H NMR: b 3.90 (s. 3H, - OCH]), 6.42(s, lH, > C - CH -), 7.20{m, 9H, Ar),
7.50(m, 3H, Ar), 7.78(t, 2H, Ar), 8.03(d, 3H, Ar).
IR(KBr)cm-': 1604(>C-N-), 1552 and 1500 (Ar).
25 'H NMR: b2.24(s, 3H, -CHJ), :pO(s, 3H, -CH3), 2.39(s, 3H, -CH]),
6.49(s, IH, >C -CH -), 7.25(m, 8H,Ar), 7.46-7.72(m, 5H,Ar), 7.96(m, 2H,
Ar).
IR(KBr) em-I: 1614 (> C - N -), and 1550 (Arl.
30 IH NMR: 66.48(5, IH, >C-CH - i, 7.27-7./9\m, 14H,Ar),8.0(m,2H,Ar),
signal due to - CH] is merged with DMSO-~ signal.
IR(KBr) em-I : 1614(>C-N-), 1586 and 1549(Ar\.
28 'H NMR :62.29 (s, 3H, - CH]), 2.40(s, 3H, - CH3), 6.46(5, IH, > C = CH - ),
7.27-7.76(m, 14H, Ar), 8.01 (m, 2H, Ar).
IR(KBr) em-I : 1618(><::-N-), i549 and 1509 (Ar).
22 'H NMR:O 3.7(5, 3H, -OCH]),6.43(s,lH, >C-CH-), 7.O{d,2H,Ar), 7.26(s,
5H, Ar), 1.31(m, 6ft Ar), 8'0{9, 3H, Ar), signal due to - CH, group is hurried un-
der ttte slgnal of DMSD-c4 at 6 2.49.
IR(KBr) em-I: 1618 (> C ~N -),1581 and i550 (Ar)
• w - Chloroform; x - ethyl acetate; y - hexane; z - pet. ether.
t Yields of 3a-3m were calculated on the basis of the amount of thiazoline used during condensation.
3a
3b
3c
3cI
3e
3f
3&
3h
3i
3j
31t
31
3m
185-90
(w)
240
(w-x; 8:2)
195
(z-w;2:8)
175
(x-w;2:8)
130
(w-x;8:2)
130
(w-x; 8:2)
100
(w-x); 5:5)
112
(w-x; 8:2)
181
(z-w;8:2)
95
(w-x;8:2)
120
(w-x;8:2)
110
(w-x;8:2)
125
(w-x; 5:5)
40 'HNMR: M.5 (5, IH, > C-CH-), 7.25(5, 5H,Ar), 7.50(m, 5H,Ar),
7.75(m, 4H, Ar), 8.10(d, 4H, Ar).
HRMS (m/z: reI. int.): 429.12841 (M+, 21.37) (CaIcd. for C18HI~3S:429.12997.
25 IHNMR: b2.3 (s, 3H, -CHJ), 2.40(s, 3H, -CH]),6.1(s, lH, >C=CH-),
7.3(m, 8H, Ar), 7.5(m, 2H, Ar). 7.7(m, 2H, Ar), 8.1(d, 2H, Ar), 8.2(d, 2H, Ar).
HRMS (m/z; rel, int.): 457.16133(M'; 100.00XCalcd. for C]OHZ3N]S:
457.16125),456.15364 (M+ - H; 12.64). 442. 13799(M+ -CH]; 7.63).
380.12305
(M' -C6HS; 6.51). 279.09501(M+ - ~ ; 5.53),105.07093 &MI ;
• ~M.
was stirred with sodium carbonate solution (10%
10 mL) for half an hour and then filtered, washed
with water and air dried. The crude product so
obtained was crystallized from chloroform to give
la as an orange yellow solid, yield 130 mg (30%),
m.p. 180°; IH NMR and HRMS (cf. Table I).
Similarly, the condensation of 9-chloro-2-meth-
ylacridine with 2-aminopyridine followed by puri-
fication by column chromatography gave com-
pound Ib; yield, m.p., solvent of elution and spec-
tral data of 1b are reported in Table I.
Condensation of 2-amino-2-thiazoline with
9-chloroacridine:Formation of 2a. 9-Chloroacri-
dine (426 mg, 2mmoles) was dissolved in metha-
nol (50 mL) and to it was added 2-amino-2-thiaz-
oline (306 mg, 3 mmoles). The reaction mixture
was heated under reflux for 16 hr. The crystalline
solid separated out was filtered. The filtrate was
evaporated and the residue left was subjected to
column chromatography over silica gel. Elution
which was hexane-chloroform (2:8) gave 2a as an
orange compound which was crystallized from metha-
nol, yield 165 mg (30%), m.p. 192-5°; IH NMR
and HRMS (cf, Table I).
Similarly 9-chloro-2-methylacridine was con-
densed with 2-amino-2-thiazoline to give 2b;
yield, m.p., solvent of elution and spectral data of
2b are reported in Table I.
General procedure for condensation of 3,
4-diaryl- 2-imino-4-thiazoline with 9-chloroacri-
dines:Formation of 3a-m. 9-Chloroacridine (426
mg, 2 mmoles was dissolved in methanol (50 mL)
and to it was added 2-imino-3, 4-diphenyl-
4-thiazoline (504 mg, 2 mmoles). The reaction
mixture was heated under reflux for 10 hr and
then solvent removed under reduced pressure.
The solid residue was dissolved in benzene (50
mL) and insoluble material filtered, washed with
benzene and air dried. This solid was found to be
2-imino- 3, 4-diphenyl-4-thiazoline hydrochloride
(250 mg). The benzene solution was concentrated
and subjected to column chromatography over si-
lica gel. Elution with chloroform gave 3a, as a
yellow coloured solid, yield 180 mg (40%), m.p.
185-90°; IH NMR and HRMS (cf. Table I).
Similarly, compounds 3b-m were prepared.
Their yields, m.ps solvents of elution and spectral
data are reported in Table I.
Anti-inflammatory actiVity testing". The test-
ing of anti-inflammatory activity was carried out
using the carrageenin-induced paw oedema meth-
od in albino rats. Oedema in one of the hind
paws was induced by injection of 0.1 mL of 1%
carrageenin solution into planter aponeurosis. The
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volume of the paw was measured plethysmogra-
phically immediately after and 3 hr after the injec-
tion of carrageenin. The difference in volume
gave the amount of oedema developed. Percent
inhibition of the oedema between the control
group and the compound (100 mg/kg p.o.) treated
group was calculated and compared with the
group receiving standard drug phenylbutazone
(30 mg/kg p.o.). At a dose of 100 mg/kg p.o.,
none of the compounds showed any significant
anti-inflammatory activity.
Analgesic activity testing". Analgesic activity
was evaluated in mice using the phenylquinone
writhing assay method". Female Swiss mice (I5-
20 g), bred in the Animal House of CDRI, Luck-
now and maintained under standard laboratory
conditions, were used in -the study. Mice were in-
jected 0.2 mL of 0.02% aqueous solution of
phenylquinone (2-phenyl-l, 4-benzoquinone) and
observed for writhing for 20 min. Number of
writhes, produced by each mouse, was counted
during this period. A minimum of 10 writhes,
produced by a mouse, was considered positive
and used in the analgesic testing on the following
day.
The mice, consisting of 5 in each group and
showing significant writhing, were given subcu-
taneously or orally 50 or 100 mg/kg dose of test
compounds, 15 min prior to phenylquinone chal-
lange. Writhing was again recorded for each
mouse in a group and percentage protection was
calculated using the following formula:
% Protection =
(
No. of writhing in treated 10)100- x o·
No. of writhing in untreated
This was taken as percent analgesic response
and was averaged in each group of mice. Percent
of animals, exhibiting analgesia 'was determined
with each dose.
Compound 3j exhibited significant analgesic ac-
tivity.
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